Understanding Lambert-Eaton Myasthenic Syndrome
Author Information
Author(s): Nils Erik Gilhus
Primary Institution: University of Bergen
Hypothesis
What are the pathogenesis, diagnosis, and therapy options for Lambert-Eaton Myasthenic Syndrome?
Conclusion
Lambert-Eaton Myasthenic Syndrome is primarily caused by autoantibodies to voltage-gated calcium channels, leading to muscle weakness, and can be treated with symptomatic therapies and immunosuppression.
Supporting Evidence
- LEMS is caused by pathogenic autoantibodies to presynaptic voltage-gated calcium channels.
- 80% of LEMS patients experience proximal weakness in both arms and legs.
- Presence of VGCC autoantibodies confirms the LEMS diagnosis due to high specificity.
- Acetylcholine esterase inhibitors can increase acetylcholine availability at the neuromuscular junction.
- Immunosuppressive therapy may be necessary if symptomatic treatment is insufficient.
- Half of LEMS patients have a paraneoplastic disorder, often linked to small cell lung carcinoma.
Takeaway
Lambert-Eaton Myasthenic Syndrome is a rare disease that makes your muscles weak because of problems with nerve signals, and doctors can help with special medicines.
Methodology
The study reviews existing literature on the pathogenesis, diagnosis, and treatment of Lambert-Eaton Myasthenic Syndrome.
Limitations
The rarity of LEMS limits the amount of research and clinical trials available.
Participant Demographics
60% of LEMS patients were males, with a mean age of debut at 58 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website